Tag: Mesothelioma News

Much to the ire of plaintiff attorneys across the country, a federal judge in New Jersey granted approval for Johnson & Johnson to move forward with its controversial bankruptcy plan involving thousands of talc-related lawsuits. This strategy will allow Johnson & Johnson to split its assets from its liabilities, putting more than 38,000 claims on […]

The post Johnson & Johnson’s Talc Bankruptcy Plan Approved appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Scientists at the University of Leicester in the United Kingdom recently published phase 2 clinical trial results involving abemaciclib, a new genetic therapy for malignant pleural mesothelioma. Researchers designed the trial to match mesothelioma treatment to a patient’s specific genetic profile. The early study results are promising for mesothelioma patients who have previously received first-line […]

The post Mesothelioma Clinical Trial Matches Treatment to Genetic Profiles appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A research team at the National Cancer Institute is developing a novel therapy that could change the treatment paradigm for pleural mesothelioma. It is a long-awaited, much-needed breakthrough. The potential intraoperative adjuvant is a spray-on hydrogel involving genetically engineered molecular nanoparticles designed to specifically target and kill tumor cells. It showed surprising efficacy in a […]

The post NCI Moving Closer to More Effective Treatment for Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Food and Drug Administration recently moved a step closer to a much-needed, stricter standardization of testing for the presence of toxic asbestos fibers in talc-containing cosmetic products. On Jan. 13, the FDA released its 124-page consensus document written by the Interagency Working Group on Asbestos in Consumer Products. It outlined a scientific assessment […]

The post FDA Looks at Stricter Testing for Asbestos in Talc appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

University of Texas MD Anderson Cancer Center in Houston is No. 1 for the seventh consecutive year on the prestigious U.S. News & World Report Best Hospitals for Cancer list. The annual cancer rankings were included in the media company’s recently published Best Hospitals 2022 guidebook. Cancer is one of the 15 specialties for which […]

The post Mesothelioma Specialty Centers Factor in 2021 Best Hospital Rankings appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The National Cancer Institute has opened a promising clinical trial aimed at increasing the effectiveness of immunotherapy treatment for patients with unresectable malignant mesothelioma. This latest study involves combining LMB-100, a manmade protein designed to kill cancer cells, with ipilimumab, an immunotherapy drug recently approved for use by the U.S. Food and Drug Administration. Ipilimumab […]

The post NCI Opens New Immunotherapy Clinical Trial for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Researchers have made significant progress in mesothelioma treatment advancements recently, including promising work with immunotherapy. The first U.S. Food and Drug Administration-approved combination immunotherapy for mesothelioma, nivolumab and ipilimumab, known by brand names Opdivo and Yervoy, has been effective for many patients. In September 2021, the European Society for Medical Oncology presented study data showing […]

The post Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A novel phase II clinical trial for malignant mesothelioma is expected to open soon and involve a versatile, biological drug already showing promise in treating severe cases of COVID-19. Oncotelic Therapeutics Inc., an innovative, immunotherapy/oncology company in Agoura Hills, California, hopes to open the mesothelioma clinical trial by March at a dozen prominent U.S. treatment […]

The post Mesothelioma Clinical Trial to Involve Drug Studied for COVID-19 appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A federal judge in North Carolina delivered a major setback to Johnson & Johnson and its controversial plan to unload all talc-related litigation in bankruptcy court through a recently-created subsidiary. Bankruptcy Judge Craig Whitley said he was “obligated” to move the case from North Carolina to New Jersey, where Johnson & Johnson is headquartered and […]

The post Court Deals Blow to Johnson & Johnson Bankruptcy Plan for Talc Cases appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, accord…

Researchers at the University of Vermont Cancer Center have uncovered a new approach to the treatment of malignant pleural mesothelioma, sparking a clinical trial that has opened with considerable anticipation. The trial involves RSO-021, a novel drug that works by inhibiting a tumor cell’s ability to manage its own toxic waste byproduct. “The key to […]

The post University of Vermont Study Opens New Door for Mesothelioma Treatment appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment. The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for […]

The post Study Supports Opdivo as Second-Line Mesothelioma Treatment appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A recently amended California law will now allow the estates of deceased plaintiffs, including mesothelioma patients, to collect pain and suffering damages. Previously, only the person who sustained bodily injury could recover pain and suffering damages. These damages are often the largest sums of money at stake in many mesothelioma lawsuits. When it becomes law on […]

The post New California Law Could Benefit Mesothelioma Plaintiffs appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

As expected, Johnson & Johnson has unloaded its burgeoning talc-related liabilities on a new subsidiary that filed for Chapter 11 bankruptcy protection on Oct. 14. The controversial move, which confirmed the fears of many personal injury attorneys, is an attempt by J&J to more easily resolve the thousands of current and future lawsuits claiming that […]

The post Johnson & Johnson Sending Talc Cases to Bankruptcy Court appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Secondary exposure to toxic asbestos has declined dramatically in recent decades, but known cases of malignant mesothelioma caused by that type of asbestos exposure have continued to climb. Increasing awareness of the rare cancer has led to the contrasting trends and an expected rise in personal injury lawsuits involving secondary asbestos exposure. “One of the […]

The post Courts Seeing More Secondary Asbestos Exposure Lawsuits appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.